Over the last few years, we have seen a groundswell of support for health equity activities from all corners of healthcare, making a focus on health equity ubiquitous throughout the industry. While most life sciences companies are taking positions on and making commitments to health equity, only about half are discussing it as a growth driver or a competitive advantage. Much of the life sciences industry’s recent activity in health equity has been on the clinical development front, including incorporating new standards required by the Food and Drug Administration (FDA) into clinical trials. One reason for this lack of commercial focus is that life sciences companies are still unclear on the financial and patient outcomes impact of health equity initiatives.
To help life sciences companies take more decisive action on health equity, the ZS Research Center conducted a study focused on identifying the health inequities and drivers of those inequities along the patient journey within and across various diseases. We believe life sciences companies can leverage the insights uncovered in our study to prioritize areas of focus, design better customer engagement programs and make a tangible impact on patient outcomes. In this white paper we offer three key initial steps life sciences can take to advance the cause of health equity on the commercial side of the business.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
